KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther financing activitiesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Vir Biotechnology (VIR) Net Income (2018 - 2025)

Historic Net Income for Vir Biotechnology (VIR) over the last 8 years, with Q3 2025 value amounting to -$163.1 million.

  • Vir Biotechnology's Net Income rose 2366.49% to -$163.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$499.7 million, marking a year-over-year increase of 631.69%. This contributed to the annual value of -$522.0 million for FY2024, which is 1514.46% up from last year.
  • Latest data reveals that Vir Biotechnology reported Net Income of -$163.1 million as of Q3 2025, which was up 2366.49% from -$111.0 million recorded in Q2 2025.
  • In the past 5 years, Vir Biotechnology's Net Income registered a high of $525.3 million during Q4 2021, and its lowest value of -$213.7 million during Q3 2024.
  • Over the past 5 years, Vir Biotechnology's median Net Income value was -$111.0 million (recorded in 2025), while the average stood at -$25.7 million.
  • In the last 5 years, Vir Biotechnology's Net Income surged by 54975.38% in 2021 and then plummeted by 22374.9% in 2022.
  • Over the past 5 years, Vir Biotechnology's Net Income (Quarter) stood at $525.3 million in 2021, then tumbled by 119.34% to -$101.6 million in 2022, then decreased by 14.14% to -$116.0 million in 2023, then increased by 9.82% to -$104.6 million in 2024, then tumbled by 55.98% to -$163.1 million in 2025.
  • Its Net Income stands at -$163.1 million for Q3 2025, versus -$111.0 million for Q2 2025 and -$121.0 million for Q1 2025.